Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

SRR8613710

— · F

f17e029b-ec1a-5a56-97f5-d42cc6bc67a2

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
F
subtype
F

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • XENOBIOTIC_METABOLISM+0.330
  • COAGULATION+0.320
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
  • HEDGEHOG_SIGNALING+0.310
  • CHOLESTEROL_HOMEOSTASIS+0.300
  • APICAL_JUNCTION+0.270
  • BILE_ACID_METABOLISM+0.270
  • ESTROGEN_RESPONSE_EARLY+0.270
  • MYOGENESIS+0.260
  • GLYCOLYSIS+0.250

Top 10 suppressed

  • E2F_TARGETS-0.550
  • INTERFERON_ALPHA_RESPONSE-0.510
  • MYC_TARGETS_V1-0.500
  • G2M_CHECKPOINT-0.460
  • INTERFERON_GAMMA_RESPONSE-0.460
  • ALLOGRAFT_REJECTION-0.360
  • PROTEIN_SECRETION-0.290
  • IL6_JAK_STAT3_SIGNALING-0.260
  • MYC_TARGETS_V2-0.240
  • TNFA_SIGNALING_VIA_NFKB-0.230

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120050118.TNBC
breast-umap@18
—F0.921
2TCGA-OL-A5D6-01A-21R-A27Q-07
breast-umap@18
—F0.867
3SRR8613741
breast-umap@18
—F0.865
4SRR8613707
breast-umap@18
—C0.853
5SRR8518125
breast-umap@18
—F0.853
6ERR2208930
melanoma-umap@29
——0.847
720040084.LumA
breast-umap@18
—A0.845
8TCGA-CV-7177-01A-11R-2016-07
head-neck@1
——0.845
9MNG965
mng-umap@100
——0.842
10TCGA-73-4675-01A-01R-1206-07
lung-landscapes@6
—cohortA20.838

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 24 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
XENOBIOTIC_METABOLISM0.330Inavolisib— uncovered
COAGULATION0.320Binimetinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.320Inavolisib— uncovered
HEDGEHOG_SIGNALING0.310Inavolisib— uncovered
CHOLESTEROL_HOMEOSTASIS0.300Remibrutinib— uncovered
APICAL_JUNCTION0.270Inavolisib— uncovered
BILE_ACID_METABOLISM0.270Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.270Inavolisib— uncovered
MYOGENESIS0.260Inavolisib— uncovered
GLYCOLYSIS0.250Inavolisib— uncovered
ADIPOGENESIS0.210Inavolisib— uncovered
KRAS_SIGNALING_DN0.210Remibrutinib— uncovered
NOTCH_SIGNALING0.210Inavolisib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.210Inavolisib— uncovered
APICAL_SURFACE0.190Temsirolimus— uncovered
HYPOXIA0.190Idelalisib— uncovered
ANGIOGENESIS0.180Remibrutinib— uncovered
ESTROGEN_RESPONSE_LATE0.180Idelalisib— uncovered
PEROXISOME0.180Idelalisib— uncovered
FATTY_ACID_METABOLISM0.150Inavolisib— uncovered